Trial record 1 of 1 for:    98110
Previous Study | Return to List | Next Study

L-Arginine Supplementation With or Without Enzyme Inhibitors Treating Erectile Function of Prostate Cancer Survivors

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Wake Forest NCORP Research Base
ClinicalTrials.gov Identifier:
NCT01105130
First received: April 14, 2010
Last updated: July 15, 2015
Last verified: July 2015
Results First Received: January 12, 2015  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Supportive Care
Conditions: Male Erectile Disorder
Prostate Cancer
Radiation Toxicity
Interventions: Drug: Placebo
Dietary Supplement: Oral L-Arginine

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Arm I - Placebo

Patients receive oral placebo twice daily (total of 6 capsules per day).

Placebo: Given orally

Arm II - Low Dose

Patients receive oral L-arginine and oral placebo twice daily (total of 3 capsules of each per day).

Placebo: Given orally

Oral L-Arginine: Given orally 3 capsules ArginMax and 3 Placebo capsules

Arm III - High Dose

Oral L-arginine twice daily = 6 capsules per day.

Oral L-Arginine: Given orally 3 capsules ArginMax and 3 Placebo capsules

Oral L-Arginine: Patients will take 6 capsules of ArginMax twice daily


Participant Flow:   Overall Study
    Arm I - Placebo     Arm II - Low Dose     Arm III - High Dose  
STARTED     48     45     47  
COMPLETED     38     34     37  
NOT COMPLETED     10     11     10  
Withdrawal by Subject                 4                 6                 2  
Never Started                 2                 2                 4  
Toxicity                 1                 3                 2  
Multiple Reasons                 3                 0                 2  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
All randomized participants

Reporting Groups
  Description
Arm I - Placebo

Patients receive oral placebo twice daily (total of 6 capsules per day).

Placebo: Given orally

Arm II - Low Dose

Patients receive oral L-arginine and oral placebo twice daily (total of 3 capsules of each per day).

Placebo: Given orally

Oral L-Arginine: Given orally 3 capsules ArginMax and 3 Placebo capsules

Arm III - High Dose

Oral L-arginine twice daily = 6 capsules per day.

Oral L-Arginine: Given orally 3 capsules ArginMax and 3 Placebo capsules

Oral L-Arginine: Patients will take 6 capsules of ArginMax twice daily

Total Total of all reporting groups

Baseline Measures
    Arm I - Placebo     Arm II - Low Dose     Arm III - High Dose     Total  
Number of Participants  
[units: participants]
  48     45     47     140  
Age  
[units: participants]
       
<=18 years     0     0     0     0  
Between 18 and 65 years     14     13     13     40  
>=65 years     34     32     34     100  
Age  
[units: years]
Median (Full Range)
  68   (48 to 78)     68   (54 to 80)     67   (53 to 80)     68   (48 to 80)  
Gender  
[units: participants]
       
Female     0     0     0     0  
Male     48     45     47     140  
Ethnicity (NIH/OMB)  
[units: participants]
       
Hispanic or Latino     1     1     0     2  
Not Hispanic or Latino     45     43     45     133  
Unknown or Not Reported     2     1     2     5  
Race (NIH/OMB)  
[units: participants]
       
American Indian or Alaska Native     0     0     0     0  
Asian     0     0     2     2  
Native Hawaiian or Other Pacific Islander     0     0     0     0  
Black or African American     13     17     17     47  
White     35     28     28     91  
More than one race     0     0     0     0  
Unknown or Not Reported     0     0     0     0  
Region of Enrollment  
[units: participants]
       
United States     48     45     47     140  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Erectile Function   [ Time Frame: 8 weeks ]

2.  Secondary:   Retention   [ Time Frame: 8 weeks ]

3.  Secondary:   Adherence   [ Time Frame: 8 weeks ]

4.  Secondary:   Quality of Life   [ Time Frame: 8 weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
None


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Dr. Doug Case
Organization: Wake Forest NCORP Research Base
phone: (336) 716-1048
e-mail: dcase@wakehealth.edu


No publications provided


Responsible Party: Wake Forest NCORP Research Base
ClinicalTrials.gov Identifier: NCT01105130     History of Changes
Other Study ID Numbers: CCCWFU 98110, U10CA081851
Study First Received: April 14, 2010
Results First Received: January 12, 2015
Last Updated: July 15, 2015
Health Authority: United States: Institutional Review Board